Payment overview · 2025
General Payments
$329.43
18 reported records · 5 companies
Healthcare provider profile · identity verified
Brian Hancock, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRANTS PASS, OR · NPI 1720088693
Verified facts
What the public records show
CMS Open Payments records show Brian Hancock, MD received $329.43 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 74.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $244.01 | 74.1% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.37 | 8.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.07 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.17 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.81 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.43 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $198.44 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 65 |
| Omeprazole | Omeprazole | 203 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 50 |
| Metformin Hcl | Metformin Hcl | 138 | 40 |
| Lisinopril | Lisinopril | 137 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 23 |
| Losartan Potassium | Losartan Potassium | 113 | 36 |
| Potassium Chloride | Potassium Chloride | 112 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 26 |
| Prednisone | Prednisone | 92 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 12 |
| Furosemide | Furosemide | 85 | 23 |
| Carvedilol | Carvedilol | 80 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 18 |
| Trazodone Hcl | Trazodone Hcl | 75 | 13 |
| Lorazepam | Lorazepam | 71 | 19 |
| Azithromycin | Azithromycin | 69 | 44 |
| Eliquis | Apixaban | 68 | 19 |
| Tramadol Hcl | Tramadol Hcl | 68 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 26 |
| Warfarin Sodium | Warfarin Sodium | 59 | 12 |
| Gabapentin | Gabapentin | 58 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Glipizide | Glipizide | 47 | 13 |
| Simvastatin | Simvastatin | 47 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 15 |
| Lovastatin | Lovastatin | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Finasteride | Finasteride | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 35 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Digoxin | Digoxin | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Famotidine | Famotidine | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Yuvafem | Estradiol | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.43 · 18 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, Kerendia, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error